Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta.
Identifying effective treatment combinations for MS patients failing standard therapy is an important goal. We report the results of a phase II open label baseline-to-treatment trial of a humanized monoclonal antibody against CD25 (daclizumab) in 10 multiple sclerosis patients with incomplete response to IFN-beta therapy and high brain inflammatory and clinical disease activity. Daclizumab was very well tolerated and led to a 78% reduction in new contrast-enhancing lesions and to a significant improvement in several clinical outcome measures.
Bielekova
Bibiana
B
Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA.
Richert
Nancy
N
Howard
Thomas
T
Blevins
Gregg
G
Markovic-Plese
Silva
S
McCartin
Jennifer
J
Frank
Joseph A
JA
Würfel
Jens
J
Ohayon
Joan
J
Waldmann
Thomas A
TA
McFarland
Henry F
HF
Martin
Roland
R
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000077561:Daclizumab; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007370:Interferon Type I / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000628:therapy*; D020528:Multiple Sclerosis, Chronic Progressive / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D011994:Recombinant Proteins
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007370:Interferon Type I; D011994:Recombinant Proteins; D000077561:Daclizumab